ACTAVIS ANNOUNCES FDA WARNING LETTER FOLLOWING FDA INSPECTION

Actavis Group, the international generic pharmaceuticals company, announced that it has received a warning letter from the U.S. Food and Drug Administration (FDA), related to its inspection of the Group's solid oral dose manufacturing facility in Little Falls, New Jersey.

Web Wire (http://www.webwire.com/ViewPressRel.asp?aId=20270)